Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human single ascending dose study of QRL-101 in healthy participants
NL-OMON53647Completed
- Sponsor
- QurAlis
- Start
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Trial of QRL-101, sponsored by QurAlis. Started Dec 2022; status: completed.
02
Drugs
QRL-101
Beyond the preview
Go deeper on NL-OMON53647.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53647.